BioMarin’s Hemophilia Gene Therapy Improves Bleeding Rates for Two Years

A single infusion of BioMarin’s Roctavian (valoctocogene roxaparvovec) reduced bleeding rates by 84 percent for two years in patients with hemophilia A, according to a study published in The New England Journal of Medicine (NEJM).
Source: Drug Industry Daily